CROs offering Phase I Clinical Trials with Biologics (Other)
29 published
29 published CROs match Phase I Clinical Trials and Biologics (Other).
Locations in this set include United States, United Kingdom, Germany, India, Australia, and Canada.
Capabilities that show up most often in this set: Phase II Clinical Trials, Phase IV / Post-Marketing, Regulatory Affairs, Clinical Operations, and Phase III Clinical Trials.
Matching companies
Raptim ResearchBioequivalence and bioavailability specialist with 32+ USFDA inspections cleared, running healthy-subject BA/BE and PK/PD studies, IVRT/IVPT in-vitro release and permeability testing, and Phase I to IV clinical trials.
Simbec-OrionFull-service CRO delivering clinical trial management across early to late phases, with specialist expertise in rare diseases and oncology.
Syneos HealthGlobal CRO with 26,000+ employees offering integrated clinical development, regulatory affairs, and commercialization services. Helped develop or commercialize 96% of FDA-approved oncology drugs and 93% of EMA-authorized oncology products in the last five years.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TFS HealthScienceGlobal mid-size CRO specializing in dermatology, internal medicine, neuroscience, oncology, and ophthalmology with Phase I-IV clinical development, real-world evidence studies, and flexible resourcing solutions across 600+ experts in Europe, North America, and Australia.
TigermedLeading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
Veeda LifesciencesVeeda Lifesciences is a contract research organization offering preclinical R&D, BA/BE and bioanalytical studies, and Phase I–IV clinical trials for innovative, biosimilar, and generic drugs. Its capabilities cover both small and large molecules, including clinical bioanalysis and real-world evidence.
Velocity Clinical ResearchIntegrated clinical research site organization operating 60+ sites across the U.S. and Europe, supporting trials that contributed to 61 FDA-approved products since 1986.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/phase-1-clinical-trials/biologics-other.md